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Background:  Small dense low density lipoprotein (sdLDL) has recently emerged as an important risk factor of coronary heart 
disease. 
Methods:  The mean LDL particle size was measured in 203 patients with type 2 diabetes mellitus (T2DM) and 212 matched 
subjects without diabetes using polyacrylamide tube gel electrophoresis. Major vascular complications were defined as stroke, 
angiographically-documented coronary artery disease or a myocardial infarction. Peripheral vascular stenosis, carotid artery 
stenosis (≥50% in diameter) or carotid artery plaque were considered minor vascular complications. Overall vascular complica-
tions included both major and minor vascular complications. 
Results:  Diabetic patients had significantly smaller mean-LDL particle size (26.32 nm vs. 26.49 nm) and a higher percentage of 
sdLDL to total LDL compared to those of subjects without diabetes (21.39% vs. 6.34%). The independent predictors of sdLDL in 
this study were serum triglyceride level and body mass index (odds ratio [OR], 1.020 with P<0.001 and OR 1.152 with P<0.027, 
respectively). However, no significant correlations were found between sdLDL and major vascular complications (P=0.342), mi-
nor vascular complications (P=0.573) or overall vascular complications (P=0.262) in diabetic subjects. 
Conclusion:  Diabetic patients had a smaller mean-LDL particle size and higher proportion of sdLDL compared to those of sub-
jects without diabetes. Obese diabetic patients with hypertriglyceridemia have an increased risk for atherogenic small dense LDL. 
However, we could not verify an association between LDL particle size and vascular complications in this study.
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INTRODUCTION
Coronary heart disease (CHD) is the leading cause of death in 
patients with type 2 diabetes (T2DM). Individuals with diabe-
tes have a 2- to 4-fold increased risk of CHD compared with 
that of non-diabetic individuals [1-3]. Moreover, there is evi-
dence that patients with diabetes with no history of CHD had 
the same risk of myocardial infarction (MI) as that observed 
in non-diabetic subjects with a history of MI [4]. This similar 
level of risk of diabetes and previous CHD has led to the sug-
gestion that individuals with diabetes should be treated as 
CHD-risk equivalents [5]. Several large-scale clinical trials 
have shown that reduction of low density lipoprotein (LDL) 
cholesterol level is crucial in reducing CHD morbidity and 
mortality in both primary and secondary prevention settings 
[5]. However, using LDL level alone is insufficient as a method 
of identifying individuals with incident CHD since approxi-
mately 50% of these events occur in subjects with normal LDL 
level [3]. This has led to the hypothesis that other factors may 
be implicated in the pathogeneses of atherosclerosis and CHD. 
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One of the underlying reasons for this increased risk in T2DM 
patients is atherogenic dyslipidemia, which is common in 
T2DM patients and is characterized by a low plasma level of 
high density lipoprotein (HDL) cholesterol, increased levels of 
serum triglycerides, specifically very low density lipoprotein 
triglycerides, and increased levels of small dense LDL (sdLDL) 
particle [6]. DM itself increases the level of sdLDL but not that 
of LDL. The sdLDLs found in T2DM are more atherogenic 
[7,8] and are associated with more than a 3-fold increase in 
the risk of CHD [9-14]. The physicochemical properties of 
sdLDL particles provide the potential for increased atheroge-
nicity. sdLDLs have easier access to the subendothelial spaces 
in the arterial walls and exhibit enhanced binding to intimal 
proteoglycans [15,16]. sdLDLs also exhibit increased suscepti-
bility to oxidation and uptake by macrophages, therefore facil-
itating the formation of foam cells [17]. Moreover, sdLDL par-
ticles undergo decreased recognition by the LDL receptor, 
which results in an increased plasma half-life that may enhance 
their ‘anchorage’ to the arterial wall, as well as increased oxida-
tion [18,19]. Furthermore, sdLDL exhibits retarded metabo-
lism compared with that of medium-sized LDL [20] and is as-
sociated with an elevated fibrinogen level [21]. Finally, an in-
verse relationship exists between LDL particle size and level of 
plasminogen activator inhibitor-1, a factor associated with im-
paired fibrinolysis and atherosclerotic disease [22]. However, 
data regarding the relationship between LDL particle size and 
vascular complications in a Korean diabetic population are 
limited to a relatively small number of patients [23-25]. There-
fore, we sought to estimate LDL particle size and risk factors 
associated with sdLDL in a larger number of Korean type 2 di-
abetic patients and matched non-diabetic controls.
METHODS
Subjects and data collection
We performed a study with 203 consecutive T2DM patients 
(145 males and 58 females) who had visited the Samsung 
Medical Center in Seoul, Republic of Korea for the treatment 
of diabetes between the dates of July 2009 and August 2010. 
Exclusion criteria included the use of lipid-lowering agents 
(statins, fibrate, nicotinic acid or ezetimibe) that might alter 
the measurements performed in this study, as well as a medi-
cal history of severe renal disease, severe hepatic disease, in-
fectious disease or malignancy. Blood samples were collected 
from these patients to measure fasting serum glucose, HbA1c, 
total cholesterol, triglycerides (TG), HDL, LDL, and LDL par-
ticle size. We retrospectively evaluated the medical records of 
each patient for information regarding their medication use, 
duration of having diabetes, history of vascular complications, 
body mass index (BMI), urine albumin/creatinine ratio, smok-
ing status (current, ex- or never-smoker) and alcohol consump-
tion (unit per day) in order to identify and evaluate the risk 
factors for vascular complications. Subjects without diabetes 
were matched for sex and by age group (e.g., 40 to 49 years, 50 
to 59 years) to the 203 diabetic patients to clarify the impact of 
DM on LDL size. The non-diabetic control subjects (defined 
as those with no history of DM diagnosis or medication and 
an HbA1c level <5.7%) were identified from the database of 
the Center for Health Promotion at the Samsung Medical 
Center. The aforementioned exclusion criteria were also ap-
plied to the non-diabetic subjects. Based on age and sex, 609 
individuals were eligible for matching, and 212 of these were 
further selected using a statistical matching tool. After routine 
analysis was performed on these patients, the remaining blood 
samples were collected for LDL subfraction analysis. Major 
vascular complications were defined as stroke, angiographical-
ly-documented coronary artery disease or myocardial infarc-
tion. Minor vascular complications were defined as peripheral 
vascular stenosis, carotid artery stenosis (≥50% in diameter) 
or carotid artery plaque. Data on vascular complications were 
collected from the patient’s medical records. Overall vascular 
complications included both major and minor vascular com-
plications. The Institutional Review Board at Samsung Medi-
cal Center approved the study protocol (2010-08-152-001). 
LDL subfraction analysis
The LDL subfraction was analyzed using polyacrylamide tube 
gel electrophoresis (Quantimetrix Lipoprint
TM; LDL System, 
Redondo Beach, CA, USA) [6], a method that has been re-
ported to be simple, cost-effective and free of inter-individual 
interpretation bias [26]. The samples were then categorized as 
either phenotype A or B based on mean LDL particle size. LDL 
subtypes 1 to 2 were predominantly large, buoyant LDLs; sub-
types 3 to 7 were predominantly sdLDLs. The mean LDL par-
ticle size for ‘phenotype A’ was greater than 26.5 nm (265 Å), 
hence considered ‘large, buoyant LDL dominant,’ while the 
mean value of particle size for ‘phenotype B’ was less than 26.5 
nm, and was therefore considered, ‘small, dense LDL domi-
nant.’ The sdLDL (subtypes 3 to 7) percentage of total LDL was 
measured as follows: 538
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  sdLDL (%)= 
Statistical analysis
Statistical analyses were performed using the PASW Statistics 
18.0 program for Windows (SPSS Inc., Chicago, IL, USA). We 
conducted a one-sample Kolmogorov-Smirnov test to verify 
the distribution of the data. All data were summarized as the 
mean±standard deviation or as a percentage, while those with 
a skewed distribution were described as a median (IQR). The 
chi-square test was used to compare the differences in vari-
ables between the two groups. Student’s t-test was used for 
continuous, normal variables. The Mann-Whitney test was 
used to test independent relationships between the variables 
that did not demonstrate normality. A two-sided P value less 
than 0.05 was considered statistically significant. Variables 
were entered into a multiple logistic regression analysis if their 
P value was less than 0.05 in the univariate analysis in order to 
assess independent associations between risk factors, size of 
LDL particles and vascular complications. Spearman’s correla-
tion analyses were used to assess the correlations between var-
ious parameters and LDL particle size.
RESULTS
The clinical and metabolic characteristics of the 203 diabetic 
patients and the 212 matched control subjects without diabe-
tes are shown in Table 1. Patients with diabetes had signifi-
cantly smaller mean LDL particle size (26.32 nm vs. 26.49 nm) 
and a higher percentage of sdLDL to total LDL compared to 
those of the non-diabetic controls (21.39% vs. 6.34%). T2DM 
patients had higher BMIs and levels of fasting glucose, HbA1c 
and TG than did the non-diabetic controls. Total cholesterol, 
HDL, and LDL levels were higher in those without diabetes, 
who also had the higher percentage of current smokers. Sex, 
age, proportion of patients with sdLDL (phenotype B) and al-
cohol consumption did not differ significantly between the 
two groups. Comparison of the baseline characteristics be-
tween the A and B LDL phenotypes in diabetic patients are 
summarized in Table 2. The phenotype B group had a higher 
BMI and higher TG and LDL levels than did the phenotype A 
group. Sex, age, duration of diabetes, fasting glucose level, 
(LDL3+LDL4+LDL5+LDL6+LDL7)
(LDL1+LDL2+LDL3+LDL4+LDL5+LDL6+LDL7) ×100
Table 1.  Baseline characteristics of the diabetic and non-dia-
betic groups
Characteristic T2DM patients 
(n=203)
Control group 
(n=212) P value
Sex, M/F 145/58 154/58 0.827
Age, yr 58.17±10.77 54.91±9.47 0.064
BMI, kg/m
2 25.09±2.83 23.39±2.59 <0.001
Fasting glucose, mg/dL 141.87±45.16 91.28±8.86 <0.001
HbA1c, % 6.90 (6.40-7.80) 5.40 (5.20-5.50) <0.001
Total cholesterol, mg/dL 179.81±32.70 197.24±31.44 <0.001
TG, mg/dL 155.89±76.75 122.78±81.55  <0.001
HDL, mg/dL 47.76±52.93 52.80±12.84 <0.001
LDL, mg/dL 110.00±31.70 122.86±27.48 <0.001
Mean LDL size, nm 26.32±0.75 26.49±0.51 0.005
sdLDL% 21.39±17.00 6.34±5.11 <0.001
Phenotype B, n (%) 108 (53.2) 104 (49.1) 0.432
Alcohol consumption, 
unit/day
0 (0-3) 1 (0-3) 0.320
Current smoker, n (%) 20 (9.9) 36 (17.0) 0.044
Values are presented as means±standard deviation except for the fre-
quency data. HbA1c and alcohol consumption are described as me-
dian (IQR). 
T2DM, type 2 diabetes mellitus; BMI, body mass index; TG, triglyc-
erides; HDL, high density lipoprotein; LDL, low density lipoprotein.
Table 2.  Comparison of the clinical and metabolic character-
istics between phenotypes A and B in diabetic patients
Characteristic Phenotype A 
(n=95)
Phenotype B 
(n=108)
P value
Sex, M/F 71/24 74/34 0.353
Age, yr 58.29±11.62 58.06±10.01 0.881
DM duration, yr 10.15±7.22 9.70±7.75 0.673
BMI, kg/m
2 24.42±2.74 25.68±2.78 0.001
Fasting glucose, mg/dL 142.42±47.82 141.38±42.91 0.871
HbA1c, % 7.35±1.43 7.23±1.35 0.546
Total cholesterol, mg/dL 175.33±34.13 183.76±31.03 0.068
TG, mg/dL 116.27±46.63 190.73±81.19 <0.001
HDL, mg/dL 52.94±16.56 43.21±12.23 <0.001
LDL, mg/dL 105.42±32.41 114.02±30.65 0.055
Urine albumin/Cr ratio 132.57±527.72 178.47±675.04 0.588
Alcohol consumption, 
unit/day
1.65±2.60 2.14±2.97 0.215
Current smoker, n (%) 7 (7.4) 13 (12.0) 0.347
Values are presented as means±standard deviation except for the fre-
quency data. 
BMI, body mass index; TG, triglycerides; HDL, high density lipopro-
tein; LDL, low density lipoprotein.539
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HbA1c, total cholesterol, LDL, urine albumin/creatinine ratio, 
smoking status and alcohol consumption did not differ be-
tween the two groups. Multivariate logistic regression analysis 
in the diabetic group identified TG (odds ratio [OR], 1.020; 
95% confidence interval [CI], 1.012 to 1.027; P<0.001) and 
BMI (OR, 1.152; 95% CI, 1.016 to 1.305; P=0.027) as indepen-
dent risk factors for sdLDL. The OR was calculated according 
to TG level and BMI as a practical method of evaluation (Table 
3). Diabetic patients with a serum TG level ≥200 mg/dL or a 
BMI ≥30 kg/m
2 had a 17-fold and a 4-fold greater risk for 
sdLDL, respectively. However, no significant association was 
found between sdLDL in diabetic subjects and major vascular 
complications (P=0.342), minor vascular complications 
(P=0.573) or overall vascular complications (P=0.262, Table 
4). Multiple stepwise regression analyses of the major vascular 
complications and other risk factors were also performed. Age 
was the only independent predictive factor of major vascular 
complications in diabetic patients (OR, 1.127; 95% CI, 1.055 
to 1.205; P<0.001). Fasting serum glucose level and levels of 
HbA1c and lipids were not significantly associated with vascu-
lar complications (data not shown). The variables significantly 
correlated with LDL size in the Spearman’s correlation analysis 
are presented in Table 5. Among these variables, TG level had 
the strongest correlation with mean LDL particle size in dia-
betic patients (correlation coefficient=-0.558, P<0.001), as 
depicted in Fig. 1. 
DISCUSSION
The results from the present study show that diabetic patients 
have smaller LDL particles and a higher level of sdLDL than 
do non-diabetic subjects. This study also confirmed an associ-
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Fig. 1.  Correlation analysis between triglycerides (TG) level 
and low density lipoprotein (LDL) size in the diabetic group.
Table 3.  Multivariate logistic regression analysis of small 
dense LDL (phenotype B) in diabetic patients (n=203)
Variable OR 95% CI P value
HDL, mg/dL 0.991 0.966-1.017 0.506
TG, mg/dL 1.020 1.012-1.027 <0.001
BMI, kg/m
2 1.152 1.016-1.305 0.027
TG, mg/dL
<150 (n=113) 1
150≤TG<200 (n=41) 4.829 2.158-10.806 <0.001
≥200 (n=49) 17.469 6.613-46.150 <0.001
BMI, kg/m
2
<25 (n=104) 1
25≤ BMI<30 (n=88) 2.457 0.725-24.698 0.109
≥30 (n=11) 4.231 1.252-4.820 0.009
OR was adjusted for age, sex, BMI, HDL, and TG.
OR, odds ratio; CI, confidence interval; HDL, high density lipopro-
tein; TG, triglycerides; BMI, body mass index; LDL, low density lipo-
protein.
Table 4.  Comparison of LDL cholesterol size and vascular 
complications in diabetic patients
Vascular complication Phenotype A 
(n=95)
Phenotype B 
(n=108) P value
Major cases 11 (11.6) 8 (7.4) 0.342
Minor cases 17 (17.9) 16 (14.8) 0.573
Overall cases 28 (29.5) 24 (22.2) 0.262
Values are presented as number (percent). 
LDL, low density lipoprotein.
Table 5.  Spearman’s correlation coefficients between mean-
LDL particle size and other clinical factors in the diabetic group
Variable Correlation coefficient P value
T2DM patients (n=203)
TG -0.558 <0.001
HDL 0.364 <0.001
BMI -0.192 0.006
LDL, low density lipoprotein; T2DM, type 2 diabetes mellitus; TG, 
triglycerides; HDL, high density lipoprotein; BMI, body mass index.540
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ation between plasma TG concentration and LDL particle size. 
However, no significant correlation was found between sdLDL 
and vascular complications in diabetic patients.
  The prevalence of sdLDL was 53.2% and 49.1% in Korean 
type 2 diabetic patients and non-diabetic subjects, respective-
ly. This figure is higher than those observed in previous studies 
[27,28] and is much higher than that in a report of healthy, 
non-diabetic Korean adults [29]. An explanation for the dif-
ference between the reported studies and our own may be due 
to the differences in the populations studied. Ethnic, dietary 
and genetic factors play an important role in the phenotypic 
expression of the plasma lipid profile. However, the well-known 
high prevalence of sdLDL in patients with diabetes was ob-
served in this study, as can be seen by the smaller mean LDL 
particle size and higher percentage of sdLDL in these patients. 
As expected, T2DM patients had lower HDL level, higher BMI 
and much higher serum glucose and HbA1c levels. However, 
total cholesterol and LDL levels were higher in the non-dia-
betic subjects. This may be explained by the higher TG levels 
and the effects of multiple medications in diabetic patients. 
Although subjects were excluded from the study if they were 
taking lipid-lowering drugs, we may have overlooked the ef-
fects of hypoglycemic agents (such as thiazolidinediones) on 
the patients’ lipid profiles. Still, it is noteworthy that those with 
diabetes had smaller LDL particles and a higher proportion of 
sdLDL even though their total cholesterol and LDL levels were 
lower than those in the control group. Diabetic patients with 
sdLDL had higher TG levels and BMI and lower HDL com-
pared to those with large buoyant LDL, a finding that is con-
sistent with those of other studies [30,31]. Those with meta-
bolic syndrome are well known for having an increased risk 
for CHD and reduced LDL size [32,33]. The low percentage of 
current smoker among our diabetic patients may have resulted 
from our consistent advice to stop smoking. 
  The independent predictors of sdLDL in T2DM patients 
were serum TG level and BMI (OR, 1.020, with P<0.001; and 
OR, 1.152, with P=0.027, respectively), which is consistent 
with the findings of previous studies on conditions associated 
with sdLDL [20,30,31,34-36]. Metabolic syndrome, insulin-
resistance and decreased adiponectin are plausible explana-
tions for this result. In regard to clinical guidance, we analyzed 
the ORs for TG and BMI according to level and found that di-
abetic patients with TG level ≥150 mg/dL and BMI ≥30 kg/
m
2 were more likely to have sdLDL. Thus, we should educate 
patients to lose weight and improve dyslipidemia through ex-
ercise and dietary restriction with the aim of blood glucose 
control. Collaboration with the Department of Sports Medi-
cine and Nutrition is essential for achieving this goal.
  Contrary to our expectations, LDL particle size and small 
LDL particle fraction failed to show any meaningful correla-
tion with vascular complications. This may be due to the cross-
sectional design of our study and because of the recently im-
proved glycemic control guidelines, which may have reduced 
vascular complications with the wide prescription of medica-
tion such as aspirin. Our attempt to divide the diabetic patients 
into three or four groups according to mean LDL particle size 
in order to analyze the correlations with vascular complica-
tions did not show any significant results (data not shown). A 
recent article by Ip et al. [37] has found that, while the LDL 
particle number was associated with incident cardiovascular 
disease, the LDL particle size and the small LDL particle frac-
tion were not consistently associated with disease incidence. 
Furthermore, there have been no studies to date that have per-
formed an adequate analysis to determine the relative or in-
cremental value of LDL subfraction measurement as a predic-
tor of cardiovascular disease compared with traditional risk 
factors. These studies also do not emphasize the clinical value 
of providing treatment based on results of LDL subfraction 
testing. From the current results, we cannot conclude that 
sdLDL is not an independent predictor of vascular complica-
tions. Longitudinal studies with a larger number of patients 
are essential to determine whether sdLDL play a crucial role in 
the development of CHD. However, it would be unethical to 
design a study in which known risk factors are not treated in 
order to verify the clinical value of LDL particle size. There-
fore, we are planning to closely observe these patients until 
death and to then re-evaluate the significance of the sdLDL.
  In agreement with other studies [38,39], TG concentration 
was the strongest determinant of LDL particle size in the pres-
ent study. This result may be due to the association of hyper-
triglyceridemia with sdLDL since the metabolism of TG-rich 
lipoprotein is the major determinant of sdLDL particle forma-
tion. LDL metabolism and particle size are associated with very 
low density lipoprotein (VLDL) metabolism. The precursor of 
sdLDL, β-pool LDL, is synthesized from VLDL1, and the pre-
cursor of the large buoyant LDL, α-pool LDL is synthesized 
from VLDL2. The synthesis of VLDL1 is increased at higher 
TG concentrations; thus, the synthesis of β-pool LDL is also 
increased when TG concentration is elevated. This β-pool 
LDL donates cholesterol to VLDL1 through a reaction with 541
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cholesteryl ester transfer protein and receives TG from VLDL1. 
Consequently, the β-pool LDL is converted to LDL when there 
is a high TG concentration and a low level of cholesterol. The 
TG is hydrolyzed by hepatic lipase and is then converted to 
small diameter sdLDL [40].
  We acknowledge the limitation of using a cross-sectional 
study design since we were not able to fully demonstrate the 
association between vascular complications and LDL particle 
size. A larger prospective study is needed to fully validate this 
association. 
In conclusion, diabetic patients had smaller mean-LDL parti-
cle size and higher proportion of sdLDL compared to those of 
non-diabetic controls. Obese diabetic patients with hypertri-
glyceridemia have an increased risk for atherogenic sdLDL. 
However, we could not verify an association between LDL 
particle size and vascular complications in this study.
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